N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
S O Rabdano
1
,
Ellina Anatolievna Ruzanova
2
,
Anastasiya E. Vertyachikh
2
,
Valeriya A. Teplykh
2
,
Alla B. Emelyanova
2
,
Alvina Nikolaevna Emelyanova
2
,
German O. Rudakov
2
,
Sergei Aleksandrovich Arakelov
2
,
Iuliia V. Pletyukhina
2
,
Iuliia Vladimirovna Pletyukhina
2
,
Nikita S. Saveliev
2
,
Nikita Savelev
2
,
Anna A. Lukovenko
2
,
Liliya N. Fakhretdinova
2
,
Liliya Niyazovna Fakhretdinova
2
,
Ariana S. Safi
2
,
E. N. Zhirenkina
2
,
Irina N Polyakova
2
,
Natalia Sergeevna Belozerova
2
,
Vladislav V. Klykov
2
,
Arina P. Savelieva
2
,
Aleksey A Ekimov
2
,
Konstantin V. Pokachalov
2
,
V A Merkulov
3
,
Sergei M Yudin
4
,
Sergey M. Yudin
4
,
Daria S. Kruchko
5
,
Igor A. Berzin
5
,
I. A. Berzin
5
,
Veronika I. Skvortsova
5
,
Ron Milo
5
5
Federal Medical-Biological Agency of Russia, Moscow, Russia.
|
Publication type: Journal Article
Publication date: 2024-11-01
scimago Q1
wos Q1
SJR: 2.046
CiteScore: 12.7
Impact factor: 11.9
ISSN: 01634453, 15322742
PubMed ID:
39341405
Abstract
Despite the success of first-generation COVID-19 vaccines targeting the spike (S) protein, emerging SARS-CoV-2 variants have led to immune escape, reducing the efficacy of these vaccines. Additionally, some individuals are unable to mount an effective immune response to S protein-based vaccines. This has created a need for alternative vaccine strategies that are less susceptible to mutations and capable of providing broad and durable protection. This study aimed to evaluate the efficacy and safety of a novel COVID-19 vaccine based on the full-length recombinant nucleocapsid (N) protein of SARS-CoV-2.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Vaccines
2 publications, 22.22%
|
|
|
International Journal of Rheumatic Diseases
1 publication, 11.11%
|
|
|
Virology
1 publication, 11.11%
|
|
|
Discover Public Health
1 publication, 11.11%
|
|
|
Journal of Infection
1 publication, 11.11%
|
|
|
Jurnal Infektologii
1 publication, 11.11%
|
|
|
Journal of Immunology
1 publication, 11.11%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 publication, 11.11%
|
|
|
1
2
|
Publishers
|
1
2
|
|
|
MDPI
2 publications, 22.22%
|
|
|
Elsevier
2 publications, 22.22%
|
|
|
Wiley
1 publication, 11.11%
|
|
|
Springer Nature
1 publication, 11.11%
|
|
|
SPRIDA
1 publication, 11.11%
|
|
|
Oxford University Press
1 publication, 11.11%
|
|
|
Frontiers Media S.A.
1 publication, 11.11%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
9
Total citations:
9
Citations from 2024:
9
(100%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Rabdano S. O. et al. N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial // Journal of Infection. 2024. Vol. 89. No. 5. p. 106288.
GOST all authors (up to 50)
Copy
Rabdano S. O. et al. N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial // Journal of Infection. 2024. Vol. 89. No. 5. p. 106288.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.jinf.2024.106288
UR - https://linkinghub.elsevier.com/retrieve/pii/S0163445324002226
TI - N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
T2 - Journal of Infection
AU - Rabdano, S O
AU - Ruzanova, Ellina Anatolievna
AU - Vertyachikh, Anastasiya E.
AU - Teplykh, Valeriya A.
AU - Emelyanova, Alla B.
AU - Emelyanova, Alvina Nikolaevna
AU - Rudakov, German O.
AU - Arakelov, Sergei Aleksandrovich
AU - Pletyukhina, Iuliia V.
AU - Pletyukhina, Iuliia Vladimirovna
AU - Saveliev, Nikita S.
AU - Savelev, Nikita
AU - Lukovenko, Anna A.
AU - Fakhretdinova, Liliya N.
AU - Fakhretdinova, Liliya Niyazovna
AU - Safi, Ariana S.
AU - Zhirenkina, E. N.
AU - Polyakova, Irina N
AU - Belozerova, Natalia Sergeevna
AU - Klykov, Vladislav V.
AU - Savelieva, Arina P.
AU - Ekimov, Aleksey A
AU - Pokachalov, Konstantin V.
AU - Merkulov, V A
AU - Yudin, Sergei M
AU - Yudin, Sergey M.
AU - Kruchko, Daria S.
AU - Berzin, Igor A.
AU - Berzin, I. A.
AU - Skvortsova, Veronika I.
AU - Milo, Ron
PY - 2024
DA - 2024/11/01
PB - Elsevier
SP - 106288
IS - 5
VL - 89
PMID - 39341405
SN - 0163-4453
SN - 1532-2742
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2024_Rabdano,
author = {S O Rabdano and Ellina Anatolievna Ruzanova and Anastasiya E. Vertyachikh and Valeriya A. Teplykh and Alla B. Emelyanova and Alvina Nikolaevna Emelyanova and German O. Rudakov and Sergei Aleksandrovich Arakelov and Iuliia V. Pletyukhina and Iuliia Vladimirovna Pletyukhina and Nikita S. Saveliev and Nikita Savelev and Anna A. Lukovenko and Liliya N. Fakhretdinova and Liliya Niyazovna Fakhretdinova and Ariana S. Safi and E. N. Zhirenkina and Irina N Polyakova and Natalia Sergeevna Belozerova and Vladislav V. Klykov and Arina P. Savelieva and Aleksey A Ekimov and Konstantin V. Pokachalov and V A Merkulov and Sergei M Yudin and Sergey M. Yudin and Daria S. Kruchko and Igor A. Berzin and I. A. Berzin and Veronika I. Skvortsova and Ron Milo and others},
title = {N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial},
journal = {Journal of Infection},
year = {2024},
volume = {89},
publisher = {Elsevier},
month = {nov},
url = {https://linkinghub.elsevier.com/retrieve/pii/S0163445324002226},
number = {5},
pages = {106288},
doi = {10.1016/j.jinf.2024.106288}
}
Cite this
MLA
Copy
Rabdano, Sevastyan O., et al. “N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.” Journal of Infection, vol. 89, no. 5, Nov. 2024, p. 106288. https://linkinghub.elsevier.com/retrieve/pii/S0163445324002226.
Profiles